^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AXA-042

    i
    Other names: AXA-042
    Associations

    News

    Trials
    Company:
    Axelia Oncology
    Drug class:
    TLR2 agonist, TLR6 agonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors (ESMO 2023)
    Conclusions AXA-042 demonstrates on-target biological activity in patient blood samples. Further biomarker analyses are ongoing and will be correlated with clinical activity in a larger number of patients.
    Clinical • IO biomarker • Metastases
    |
    TLR2 (Toll Like Receptor 2)
    |
    Inflammatory gene signature
    |
    nCounter® PanCancer IO 360™ Panel
    |
    AXA-042
    2years
    Systemic administration of AXA-042, a novel TLR2/6 agonist, reshapes the tumor microenvironment, as revealed by single cell sequencing analysis. (SITC 2022)
    AXA-042 has completed GLP toxicology studies and is currently undergoing evaluation in a Phase 1 clinical trial (ACTRN12622000993796) in advanced solid tumors. Trial Registration ACTRN12622000993796 Ethics Approval The study was approved by the Austin Health Animal Ethics Committee, approval number 05640.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • TLR2 (Toll Like Receptor 2)
    |
    AXA-042